Survey Results and Recommendations from Japanese Stakeholders for Good Clinical Practice Renovation

Kenichi Nakamura, Hitoshi Ozawa, Taro Shibata, Nobuko Ushirozawa, Tomomi Hata, Natsuko Okita, Nozomu Fuse, Norihiro Sato, Koji Ikeda, Hideki Hanaoka, Tatsuya Maruyama, Michihiko Wada, Shinobu Shimizu, Hiroi Kasai, Yoichi Yamamoto, Jun Sakurai, Koji Todaka, Shimon Tashiro, Haruko Yamamoto

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Background: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is undertaking a major revision of ICH E6 Good Clinical Practice (GCP) decided to involve external stakeholders in ICH-GCP renovation. Activities such as surveys and public conferences have taken place in the United States, European Union, and Japan. For stakeholder engagement in Japan, a designated research group conducted a survey of academic stakeholders. Methods: A total of 105 academic stakeholders from 18 institutions responded to the survey. The research group developed recommendations reflecting the survey results and the opinions from patients and the public. Results: The survey showed the top four principles needing renovation were (i) informed consent (Chapter 2.9, 12.4% of respondents believed it needed renovation), (ii) systems for quality assurance (Chapter 2.13, 9.5%), (iii) information on an investigational product (Chapter 2.4, 5.7%), and (iv) procedures on clinical trial information (Chapter 2.10, 5.7%). The top three sections identified as needing renovation were: (i) informed consent (Chapter 4.8, 27.6%), (ii) monitoring (Chapter 5.18, 22.9%), and (iii) composition, functions, and operations of the ethics committee (Chapter 3.2, 14.3%). Recommendations included clarification of ICH-GCP’s scope, proportionality in various aspects of clinical trials, diversity and liquidity of ethics committee members, modernization of informed consent procedures, variations in monitoring, and regulatory grade when using real-world data. Conclusion: The recommendations from Japanese investigators and patients have been submitted to the ICH E6 Expert Working Group, which will strengthen the robustness of the GCP renovation.

Original languageEnglish
Pages (from-to)220-229
Number of pages10
JournalTherapeutic Innovation and Regulatory Science
Volume56
Issue number2
DOIs
Publication statusPublished - 2022 Mar

Keywords

  • Clinical trial regulation
  • Good Clinical Practice
  • International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
  • Real-world data
  • Remote monitoring

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Survey Results and Recommendations from Japanese Stakeholders for Good Clinical Practice Renovation'. Together they form a unique fingerprint.

Cite this